Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars?Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API), and medical diagnostic products worldwide. The company operates through three segments: Consumer Healthcare, Rx Pharmaceuticals, and API. The Consumer Healthcare segment offers OTC pharmaceutical and nutritional products, which include analgesic, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid, and vitamin and nutritional supplement products. The Rx Pharmaceuticals segment develops, manufactures, and markets generic prescription drug products, including creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquid suspensions, and solutions, as well as nasal sprays, oral liquids, and transdermal products. The API segment engages in the development, manufacture, and marketing of APIs used by the generic drug industry and branded pharmaceutical companies. Perrigo Company also manufactures and markets branded prescription drugs; and imports pharmaceutical, diagnostics, and other medical products. The company has collaborative agreements with Medicis Pharmaceutical Corporation, Medimetriks Pharmaceuticals, Cobrek Pharmaceuticals, and Cephalon Inc. Its customers primarily include retail drug companies, supermarkets, wholesalers, chain drug stores, hospitals and hospital systems, mass merchandise chains, and group purchasing organizations. The company was founded in 1887 and is headquartered in Allegan, Michigan.